A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants
22 januari 2019 uppdaterad av: Janssen Research & Development, LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants
The purpose of this study is to evaluate safety and tolerability of JNJ-64991524 compared with placebo after administration of single ascending oral doses of JNJ-64991524 (Part 1) and multiple ascending oral doses of JNJ-64991524 (Part 2) in healthy participants.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
- Läkemedel: JNJ-64991524 Dose Level 1
- Läkemedel: Placebo
- Läkemedel: JNJ-64991524 Dose Level 2
- Läkemedel: JNJ-64991524 Dose Level 3
- Läkemedel: JNJ-64991524 Dose Level 4
- Läkemedel: JNJ-64991524 Dose Level 5
- Läkemedel: JNJ-64991524 Dose Level 6
- Läkemedel: JNJ-64991524 Dose Level 7
- Läkemedel: JNJ-64991524 Dose Level 8
- Läkemedel: JNJ-64991524 Dose Level 9
Studietyp
Interventionell
Inskrivning (Faktisk)
86
Fas
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Antwerpen, Belgien, 2060
- SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg)
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 60 år (Vuxen)
Tar emot friska volontärer
Ja
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Weigh at least 50 kilogram (kg), and have a body mass index (BMI) of 18 kg/ meter (m)^2 to 30 kg/m^2, inclusive, at screening
- Be otherwise healthy on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening and Day-1. This determination must be recorded in the participant's source documents and initialed by the investigator
- Be otherwise healthy on the basis of clinical laboratory tests performed at screening and Day -1. If the results of the serum chemistry panel, including liver enzymes, white blood cell count and hematocrit, coagulation, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and confirmed initialed by the investigator
- Have the platelet count pretreatment clinical laboratory values not below the normal range during Screening and Day -1
- A woman must have a negative serum pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) at screening and a negative urine pregnancy test on Day -2
Exclusion Criteria:
- History of liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Known allergies, hypersensitivity, or intolerance to JNJ-64991524 or its excipients
- History of severe allergic reaction, angioedema, or anaphylaxis to drugs or food
- Has a history of malignancy before screening. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or a malignancy which is considered cured with minimal risk of recurrence
- Has a history of or is infected with human immunodeficiency virus (HIV [positive serology for HIV antibody]); tests positive for hepatitis B virus (HBV) infection; has antibodies to hepatitis C virus (HCV) at screening
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Cohort 1:JNJ-64991524 Dose Level (DL) 1 or Placebo(SAD Part 1)
Participants will receive a single oral dose (Dose level 1) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
|
Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
|
|
Experimentell: Cohort 2: JNJ-64991524 DL 2 or Placebo (SAD Part 1)
Participants will receive a single oral dose (Dose level 2) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.
|
|
Experimentell: Cohort 3: JNJ-64991524 DL 3 or Placebo (SAD Part 1)
Participants will receive a single oral dose (Dose level 3) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.
|
|
Experimentell: Cohort 4:JNJ-64991524 DL 4 or Placebo (SAD Part 1:Fasted-Fed)
Participants will receive a single oral dose (Dose level 4) of either JNJ-64991524 or placebo capsules in a fasted condition on Day 1 and fed condition, on Day 7.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.
|
|
Experimentell: Cohort 5: JNJ-64991524 DL 5 or Placebo (SAD Part 1)
Participants will receive a single oral dose (Dose level 5) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.
|
|
Experimentell: Cohort 6: JNJ-64991524 DL 6 or Placebo (SAD Part 1)
Participants will receive a single oral dose (Dose level 6) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
|
|
Experimentell: Cohort 1: JNJ-64991524 DL 7 or Placebo (MAD Part 2)
Participants will receive an oral dose (Dose level 7) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and pharmacokinetics (PK) from Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.
|
|
Experimentell: Cohort 2: JNJ-64991524 DL 8 or Placebo (MAD Part 2)
Participants will receive an oral dose (Dose level 8) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.
|
|
Experimentell: Cohort 3: JNJ-64991524 DL 9 or Placebo (MAD Part 2)
Participants will receive an oral dose (Dose level 9) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
|
|
Experimentell: Cohort 4: JNJ-64991524 DL 6 or Placebo (MAD Part 2)
Participants will receive an oral dose (Dose level 6) of JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined by tolerability and PK from Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Part 1: Single Ascending Dose (SAD): Number of Participants with Treatment Emergent Adverse Events (AEs) as a Measure of Safety and Tolerability
Tidsram: Up to Day 20
|
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Treatment-emergent were events between administration of study drug and up to Day 20 that were absent before treatment or that worsened relative to pre-treatment state.
|
Up to Day 20
|
|
Part 2: Multiple Ascending Dose (MAD): Number of Participants with Treatment Emergent Adverse Events as a Measure of Safety and Tolerability
Tidsram: Up to Day 28
|
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Treatment-emergent were events between administration of study drug and up to Day 28 that were absent before treatment or that worsened relative to pre-treatment state.
|
Up to Day 28
|
|
Number of Participants with Abnormalities in Vital Signs, Physical Examinations, Electrocardiogram (ECG), Cardiac Telemetry and Clinically Significant Laboratory Findings
Tidsram: Pre-dose, up to Day 20 (SAD) and up to Day 28 (MAD)
|
Number of participants with abnormalities in vital signs, physical examinations, ECG, cardiac telemetry and clinically significant laboratory findings will be measured.
|
Pre-dose, up to Day 20 (SAD) and up to Day 28 (MAD)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Plasma Concentration of JNJ-64991524
Tidsram: Pre-dose, up to Day 20 (SAD) and up to Day 28 (MAD)
|
Plasma concentration assessment will be done to characterize the pharmacokinetics (PK) of JNJ-64991524.
|
Pre-dose, up to Day 20 (SAD) and up to Day 28 (MAD)
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
15 november 2017
Primärt slutförande (Faktisk)
20 november 2018
Avslutad studie (Faktisk)
20 november 2018
Studieregistreringsdatum
Först inskickad
15 november 2017
Först inskickad som uppfyllde QC-kriterierna
15 november 2017
Första postat (Faktisk)
17 november 2017
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
24 januari 2019
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
22 januari 2019
Senast verifierad
1 januari 2019
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- CR108376
- 2017-000229-11 (EudraCT-nummer)
- 64991524EDI1001 (Annan identifierare: Janssen Research & Development, LLC)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .